Tagraxofusp, azacitidine, and venetoclax for blastic plasmacytoid dendritic cell neoplasm.
Andrew A Lane, Marlise R Luskin, Julia Keating et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 2 clinical trial evaluated tagraxofusp, azacitidine, and venetoclax in 27 patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): 16 previously untreated and 11 with relapsed or refractory disease. Composite complete remission rates were 88% in previously untreated patients and 64% in relapsed/refractory patients. Median duration of response was not reached in the untreated cohort and was 7.2 months in the relapsed/refractory cohort. Capillary leak syndrome occurred in 15%, mostly at grade 2. The authors describe the regimen as active in both groups, with a manageable safety profile.
Key findings
- Composite complete remission rates were 88% in previously untreated patients and 64% in relapsed/refractory patients.
- Median duration of response was not reached in previously untreated patients and was 7.2 months in relapsed/refractory patients.
- In the previously untreated cohort, 2-year overall survival was 65% and 2-year progression-free survival was 53%.
- Capillary leak syndrome occurred in 15% of patients; most cases were grade 2.
Why it matters
BPDCN is an aggressive malignancy, and these results suggest that combining a CD123-directed agent with azacitidine and venetoclax can produce remissions in both untreated and relapsed/refractory disease. The reported survival and response outcomes, alongside the observed safety profile, provide clinically relevant evidence for further evaluation of this combination in a disease with limited treatment options.
What to keep in mind
The phase 2 study included 27 patients and had no comparator group, limiting conclusions about comparative efficacy.